New approach, not yet tested in humans, aims to restore immune-powering B cells in cancer patients following successful CAR T-cell therapy
Oct. 17, 2016
| By Bill Briggs / Fred Hutch News Service
Scientists at Fred Hutch, Seattle Children’s Research Institute, and Technical University of Munich showed that activating a “kill switch” can turn off CAR T cells after doctors deem a cancer defeated, allowing normal B cells to again flourish.
Applicants wanted for most inclusive fellowship program among top cancer centers; Dr. Oliver Press honored as new Giuliani/Press Endowed Chair; possible new path to targeted therapies for certain leukemias, myelodysplastic syndrome.
Notable accomplishments: Dr. Hans-Peter Kiem and colleagues explore new source of stem cells and gene therapy; Dr. Justin Taylor publishes a paper describing the path or paths individual naive B cells can take to maturity; Graduate student Nitobe London among 2015 Weintraub award winners